Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.61 |
| ▸ | APP | P05067 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | RARA | P10276 | 2/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874096 | 1.00 | MAPT (0.61) | MAPTAPPSMN1; SMN2RARARARB | |
| SCHEMBL23364355 | 0.86 | MAPT (0.57) | MAPTAPPSMN1; SMN2TP53KDM4E | |
| SCHEMBL29453158 | 0.86 | MAPT (0.57) | MAPTAPPSMN1; SMN2TP53KDM4E | |
| SCHEMBL23386266 | 0.82 | MAPT (0.46) | MAPTAPPSMN1; SMN2TP53THRB | |
| SCHEMBL29453161 | 0.78 | MAPT (0.43) | MAPTAPPRARARARBRARG | |
| SCHEMBL23364370 | 0.78 | MAPT (0.43) | MAPTAPPRARARARBRARG | |
| SCHEMBL23364484 | 0.77 | MAPT (1.00) | MAPTSNCA | |
| SCHEMBL23364414 | 0.77 | MAPT (1.00) | MAPTSNCA | |
| SCHEMBL23364549 | 0.77 | MAPT (1.00) | MAPTSNCA | |
| SCHEMBL29453189 | 0.77 | MAPT (1.00) | MAPTSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2025-08-05 | — | — | US | disclosed |
| EP-4337259-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-05-09 | — | — | US | disclosed |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-4058065-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2022-09-21 | — | — | EP | disclosed |
| US-20220280650-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20220267316-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-08-25 | — | — | US | disclosed |
| US-11291732-B1 | Compounds for degrading α-synuclein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (HK) | 2022-04-05 | — | — | US | disclosed |
| WO-2021097243-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280650-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | SNCA, PARK7, PRNP | MAPT 22/4885APP 68/4885SMN1; SMN2 13/4885 |
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | SNCA, PARK7, PRNP | MAPT 22/4885APP 68/4885SMN1; SMN2 13/4885 |
| US-20220267316-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | MAPT 1/4885APP 3/4885SMN1; SMN2 191/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | MAPT 1/4885APP 3/4885SMN1; SMN2 191/4885 |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | MAPT, PRNP, APP | MAPT 1/4885APP 3/4885SMN1; SMN2 191/4885 |
| US-11291732-B1 | Compounds for degrading α-synuclein aggregates and uses thereof | SNCA, PARK7, PRNP | MAPT 18/4885APP 65/4885SMN1; SMN2 16/4885 |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | MAPT 1/4885APP 3/4885SMN1; SMN2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.